ZG006

Phase 3Small molecule

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

ZG006 is one of 129 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 1

Active, not recruiting

Neuroendocrine CarcinomaPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

ZG006

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Neuroendocrine Carcinoma

NCT05978284

Q2 2027

Phase 1Recruiting

Small Cell Lung Cancer

NCT06592638

Q3 2027

Phase 1/2Recruiting

Neuroendocrine Carcinoma

NCT07038096

Q4 2027

Phase 2Not yet recruiting

Prostate Cancer

NCT07024277

Phase 1Not yet recruiting

Lung Cancer

NCT07231445

Clinical

Trials by Indication[1]

Neuroendocrine Carcinoma4 trials

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT05978284·54 enrolled

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06283719·265 enrolled

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07038096·350 enrolled

Show 1 more trial

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06440057·78 enrolled

Small Cell Lung Cancer2 trials

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT07189455·420 enrolled

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT06592638·30 enrolled

Prostate Cancer1 trial

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT07024277·60 enrolled

Lung Cancer1 trial

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT07231445·100 enrolled

Advanced Solid Tumors1 trial

Study of ZGGS34 in Participants With Advanced Solid Tumors

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT07258121·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for ZG006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZG006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZG006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Zelgen Biopharmaceuticals Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

ZG006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Neuroendocrine Carcinoma4 trials

Small Cell Lung Cancer2 trials

Prostate Cancer1 trial

Lung Cancer1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News